US · MANE · BIOTECHNOLOGY
Veradermics, Incorporated (MANE) intrinsic value and stock valuation
$119.52as of 2026-11-21 · Mkt cap 4.65B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Veradermics, Incorporated DCF and intrinsic value
InvestorsCraft values MANE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MANE’s statements →
Veradermics, Incorporated Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2023–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Travere Therapeutics, Inc. (TVTX) $47.00
- Cybin Inc. Common Stock (HELP) $6.11
- Ovid Therapeutics Inc. (OVID) $2.20
- Abeona Therapeutics Inc. (ABEO) $2.42
- Polaryx Therapeutics, Inc. Common Stock (PLYX) $1.33
- XTL Biopharmaceuticals Ltd. (XTLB) $1.37
- Lisata Therapeutics, Inc. (LSTA) $0.90
- Adial Pharmaceuticals, Inc. (ADIL) $5.05
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Operating income | -$-72.35M | -$-26.78M | -$-17.32M |
| Net income | -$-70M | -$-26.49M | -$-16.49M |
| EPSd | -$-2M | -$-131.58K | -$-81.91K |
| Operating cash flow | -$-71.6M | -$-23.69M | -$-13.51M |
| Capital expenditure | -$-20K | $0.00 | $0.00 |
| Free cash flow | -$-71.63M | -$-23.69M | -$-13.51M |
| Total assets | $152.6M | $59.4M | $18.5M |
| Total debt | $0.00 | $0.00 | $790K |
| Net debt | -$-21.76M | -$-53.08M | -$-15.51M |
| Total equity | -$-121.01M | $54.7M | $14.6M |
| Cash and short-term investments | $141.9M | $53.1M | $16.3M |
Income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $62.1M | $23.3M | $15M |
| Selling, general and administrative expenses | $10.3M | $3.5M | $2.35M |
| Other expenses | $0.00 | $0.00 | $0.00 |
| Operating expenses | $72.4M | $26.8M | $17.3M |
| Cost and expenses | $72.4M | $26.8M | $17.3M |
| Interest income | $1.56M | $480K | $870K |
| Interest expense | $0.00 | $580K | $40K |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 |
| Ebitda | -$-70M | -$-25.9M | -$-16.45M |
| Operating income | -$-72.35M | -$-26.78M | -$-17.32M |
| Total other income/expenses, net | $2.35M | $290K | $830K |
| Income before tax | -$-70M | -$-26.49M | -$-16.49M |
| Income tax expense | $0.00 | $0.00 | $0.00 |
| Net income | -$-70M | -$-26.49M | -$-16.49M |
| Weighted average shares outstanding | $35.1M | $201.3M | $201.3M |
| Weighted average diluted shares outstanding | $35.1M | $201.3M | $201.3M |
Balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Cash and short-term investments | $141.9M | $53.1M | $16.3M |
| Net receivables | $1.25M | $1.38M | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 |
| Total current assets | $152.5M | $55.5M | $17.6M |
| Property, plant and equipment, net | $120K | $0.00 | $0.00 |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $3.85M | $890K |
| Total non-current assets | $120K | $3.85M | $890K |
| Total assets | $152.6M | $59.4M | $18.5M |
| Accounts payable | $2.13M | $2.25M | $1.85M |
| Short-term debt | $0.00 | $0.00 | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $9.15M | $4.72M | $3.05M |
| Long-term debt | $0.00 | $0.00 | $790K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $264.5M | $99.3M | $790K |
| Capital lease obligations | $0.00 | $0.00 | $0.00 |
| Total liabilities | $273.6M | $4.72M | $3.84M |
| Common stock | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-123.42M | -$-49.23M | -$-22.74M |
| Accumulated other comprehensive income (loss) | $60K | $0.00 | $0.00 |
| Total equity | -$-121.01M | $54.7M | $14.6M |
| Total investments | $120.1M | $3.85M | $890K |
| Total debt | $0.00 | $0.00 | $790K |
| Net debt | -$-21.76M | -$-53.08M | -$-15.51M |
Cash flow statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Net income | -$-70M | -$-26.49M | -$-16.49M |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 |
| Stock-based compensation | $1.44M | $250K | $210K |
| Change in working capital | -$-3.89M | $730K | $920K |
| Accounts receivable | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-120K | $650K | $1.35M |
| Net cash provided by operating activities | -$-71.6M | -$-23.69M | -$-13.51M |
| Investments in property, plant and equipment | -$-20K | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-118.86M | $0.00 | $0.00 |
| Common stock issued | $160K | $52.8M | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $159.1M | $60.5M | $13.9M |
| Net change in cash | -$-31.32M | $36.8M | $390K |
| Cash at end of period | $21.8M | $53.1M | $16.3M |
| Operating cash flow | -$-71.6M | -$-23.69M | -$-13.51M |
| Capital expenditure | -$-20K | $0.00 | $0.00 |
| Free cash flow | -$-71.63M | -$-23.69M | -$-13.51M |
Line items
Line items
Line items
About Veradermics, Incorporated
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
- CEO
- Reid Waldman
- Employees
- 21
- Beta
- 1.35
Explore
Frequently asked questions
What is the intrinsic value of Veradermics, Incorporated (MANE)?
InvestorsCraft does not currently publish an intrinsic value for MANE. How the IC value is calculated.
Is MANE undervalued?
InvestorsCraft does not publish an undervaluation signal for MANE at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.